IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers.

ABSTRACT:

Background

Oncogenic mutations in the RAS gene are associated with uncontrolled cell growth, a hallmark feature contributing to tumorigenesis. While diverse therapeutic strategies have been diligently applied to treat RAS-mutant cancers, successful targeting of the RAS gene remains a persistent challenge in the field of cancer therapy. In our study, we discover a promising avenue for addressing this challenge.

Methods

In this study, we tested the viability of several cell lines carrying oncogenic NRAS, KRAS, and HRAS mutations upon treatment with IkappaBalpha (IκBα) inhibitor BAY 11-7082. We performed both cell culture-based viability assay and in vivo subcutaneous xenograft-based assay to confirm the growth inhibitory effect of BAY 11-7082. We also performed large RNA seque

SUBMITTER: Guruvaiah P 

PROVIDER: S-EPMC11233160 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature